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Abstract
Current pharmacological interventions for pulmonary arterial hypertension (PAH) require
continuous infusions, multiple inhalations, or oral administration of drugs that act on various
pathways involved in the pathogenesis of PAH. However, invasive methods of administration,
short duration of action, and lack of pulmonary selectivity result in noncompliance and poor
patient outcomes. In this study, we tested the hypothesis that encapsulation of an investigational
anti-PAH molecule fasudil (HA-1077), a Rho-kinase inhibitor, into liposomal vesicles results in
prolonged vasodilation in distal pulmonary arterioles. Liposomes were prepared by hydration and
extrusion method and fasudil was loaded by ammonium sulfate-induced transmembrane
electrochemical gradient. Liposomes were then characterized for various physicochemical
properties. Optimized formulations were tested for pulmonary absorption and their
pharmacological efficacy in a monocrotaline (MCT) induced rat model of PAH. The entrapment
efficiency of optimized liposomal fasudil formulations was between 68.1±0.8% and 73.6±2.3%,
and the cumulative release at 37°C was 98–99% over a period of 5 days. Compared to intravenous
(IV) fasudil, a ~10 fold increase in the terminal plasma half-life was observed when liposomal
fasudil was administered as aerosols. The t1/2 of IV fasudil was 0.39±0.12 h. and when given as
liposomes via pulmonary route, the t1/2 extended to 4.71±0.72 h. One h after intratracheal
instillation of liposomal fasudil, mean pulmonary arterial pressure (MPAP) was reduced by
37.6±5.7% and continued to decrease for about 3 h, suggesting that liposomal formulations
produced pulmonary preferential vasodilation in MCT induced PAH rats. Overall, this study
established the proof-of-principle that aerosolized liposomal fasudil is a feasible option for a non-
invasive, controlled release and pulmonary preferential treatment of PAH.
© 2012 Elsevier B.V. All rights reserved.
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1. INTRODUCTION
Current therapeutic intervention for pulmonary arterial hypertension (PAH), a debilitating
disorder of the pulmonary circulation, involves use of various categories of drugs that
include prostacyclin analogues, endothelin receptor antagonists (ERAs), nitric oxide (NO)
and phosphodiesterase-5 (PDE-5) inhibitors [1]. Unfortunately, none of these medications is
optimal with regard to ease of administration, pulmonary selectivity, drug stability, safety,
and efficacy. Systemic exposure produces many off-target effects, including peripheral
vasodilation and reduced cardiac function. Consequently, existing anti-PAH therapy fails to
prevent progression of the disease, and patient morbidity and mortality remain unacceptably
high [2]. In fact, an inhalable formulation that can deliver drugs directly to the lungs at a
reduced dosing frequency would address many limitations associated with current drug
delivery approach for the treatment of PAH. Indeed, based on this assumption, we and
others have attempted to use polymeric nano- or microparticles, liposomes and nanomicelles
for inhalational therapy of PAH [3–5]. Further, aerosolized PEG-PLGA nanoparticles
containing nuclear factor kappa-B (NF-κB) oligodeoxynucleotides (ODNs) reduced
pulmonary arterial remodeling [4], and nanoparticles of pitavastatin exhibited
vasculoprotective effects [3] in MCT induced PAH rats.
Similar to polymeric particles, liposomes have also been studied for their potential in
inhalation therapy [6, 7]. As inhalational carriers, liposomes are well tolerated by the lungs
because lipids used to prepare liposomes dissolves readily in the respiratory fluid and serve
as pulmonary surfactants [8]. Further, liposomes are stable lipidic carriers because particles
in liposomal system are kinetically entrapped rather than thermodynamically equilibrated
[9]. For many years, liposomes have been used for the delivery of antimicrobial agents to the
lungs [10] and various peptides and small molecular weight drugs to produce systemic
effects [11]. Liposomes have also been used for inhalational delivery of anti-PAH drugs
such as iloprost [12] and vasoactive peptides [13].
Recently, Rho-kinase inhibitors have emerged as a new class of drugs with encouraging
potential for the treatment of PAH. Fasudil, a Rho-kinase inhibitor, has been found to
produce pulmonary vasodilation in both animal model and human PAH [14]. This drug
alleviates the symptoms of PAH by eliciting pulmonary vasodilation and down-regulating
the expression of growth factors, cell proliferation markers, and matrix proteins, and up-
regulating the expression of apoptotic markers. However, similar to prostacyclins,
intravenous fasudil is not selective for the pulmonary circulation and has a half-life of ~45
minutes [15]. Although inhalation of this new anti-PAH therapeutic agent has shown
potential for pulmonary selective vasodilation, there is no report regarding development of a
long-lasting inhalational formulation for fasudil. Currently, it is not known whether fasudil
encapsulated in liposomes will be effective in the treatment of PAH. In this study, we sought
to test the hypothesis that fasudil encapsulated in aerosolized liposomes is a viable and
efficacious approach for producing prolonged pulmonary selective vasodilation in PAH. In
this regard, we have prepared fasudil liposomes, characterized their physical properties,
investigated cellular uptake and tested their pharmacological efficacy in a rodent model of
PAH.
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2. MATERIALS AND METHODS
2.1. Materials
Lipids, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and cholesterol from ovine
wool (CHOL) were purchased from Avanti polar lipids, Inc. (Alabaster, Alabama, USA).
Fasudil monohydrochloride and monocrotaline (MCT) were purchased from LC labs, Inc.
(Woburn, MA, USA) and Sigma-Aldrich, Inc. (St. Louis, MO), respectively. Sephadex-
G-25 PD-10 pre-packed column was purchased from GE Healthcare (Piscataway, New
Jersey, USA). All other chemicals including chloroform, methanol, phosphate buffered
saline (PBS 1X), ammonium sulfate, ammonium thiocyanate, ferric chloride, acetonitrile,
dimethyl sulfoxide (DMSO), and perchloric acid were of analytical grade and obtained from
various vendors in the United States. All chemicals were used without further purification.
2.2. Preparation of liposomes
Liposomes were prepared using DPPC:CHOL at a molar ratio of 7:3, and the total lipid
concentration was 30 mM. Briefly, lipids were dissolved in a 4:1 mixture of chloroform and
methanol and dried overnight at 40°C to form a thin film in a round bottom flask using a
rotary evaporator (Buchi Rotor Evaporator R-114; BUCHI Labortechnik AG, Switzerland).
The drug was incorporated either by passive or active loading. For passive loading, dried
film was rehydrated with fasudil (15 mg/ml) in PBS and the rehydrated film was sonicated
for 1 h at 25°C (Formulation F-1 in Table 1). Large multilamellar vesicles were extruded
through LiposoFast® Extruder (Avestin, Inc., Canada) at 65°C. Small unilamellar vesicles
(SUVs) were collected following 21 cycles of extrusion from the opposite side of the
extruder. Unencapsulated drug was removed by passing drug loaded liposomes through
Sephadex-G-25 PD-10 column equilibrated with PBS (1×, pH 7.4). In case of active loading,
dried lipid film was first rehydrated with 250 mM ammonium sulfate (NH4)2SO4 solution at
varying pH (5.4, 3.0, 7.0 and 8.0), and the resulting liposomes were extruded as described
above and a transmembrane gradient was generated by exchanging external ammonium
sulfate with ammonium ion free PBS solution using PD-10 column (Formulations F-2 to
F-5). The drug was encapsulated by incubating it with ammonium sulfate entrapped
liposomes for 30 minutes at 65°C and unentrapped drug was separated using the same
column. Drug loaded liposomes were concentrated using Amicon Ultra centrifugal filter
units (MWCO-3000, Millipore Inc., Billerica, Massachusetts, USA) by centrifugation for 45
min at 1500 rpm (Centrifuge 5702-R, Eppendorf AG, Hamburg, Germany). Liposomes thus
prepared were stored at 4°C for future studies.
2.3. Physicochemical characterization
For determination of entrapment efficiency, liposomes (10µl) were lysed in methanol
(990µl), sonicated, and centrifuged to separate the drug from the lipids. The amount of
fasudil in supernatant was measured at 320 nm using a UV spectrophotometer (UV/Vis 918,
GBC Scientific Equipment, Hampshire, Illinois, USA). The amount of lipid was determined
from a standard curve prepared using phospholipid. The average vesicle size, polydispersity
and zeta potential of the liposomes were determined using a Malvern Zetasizer (Malvern®
Instruments Limited, Worcestershire, UK). The morphology of the liposomal formulations
was studied by a Transmission Electron Microscope (TEM) (Hitachi H-7650, Hitachi High
Technologies America, Inc., Pleasanton, CA). The in-vitro drug release studies were
performed in dialysis cassettes (Slide-A-Lyzer, 3500 MWCO, 0.1–0.5 ml, Thermo-
Scientific, Waltham, MA) as reported previously [16]. Briefly, the dialysis cassettes were
first hydrated with PBS (pH 7.4) and 500 µl of liposomes were loaded with a syringe. Plain
fasudil was used as a control to evaluate whether dialysis cassettes themselves have any
influence on drug release. Cassettes were immersed in 100 ml PBS in a beaker and
incubated at 37°C with moderate stirring. Samples were drawn at predetermined time
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intervals and the media was immediately replenished with fresh PBS. The amount of drug
released was estimated spectrophotometrically as described above. The stability of fasudil-
loaded liposomes was evaluated for 4 weeks. For this study, liposomes (500 µl) were stored
at 4°C and 25°C and samples were withdrawn on day 0, 7, 14, 21 and 28 and analyzed for
particle size and drug content as described above. Further, liposomal stability after
aerosolization was evaluated with a PennCentury Microsprayer® (Model IA–1B,
PennCentury, PA). Briefly, an aliquot of liposomal sample in the form of suspension was
aerosolized five times using the microsprayer device and fine droplets were collected in an
Eppendorf® tube which were evaluated for vesicle size, polydispersity index and
entrapment efficiency as described above.
2.4. Uptake of liposomes by rat alveolar macrophages and pulmonary arterial smooth
muscle cells
Uptake of liposomes by macrophages was evaluated by incubating the liposomes containing
FITC-Dextran with rat alveolar macrophages collected from the lungs of anesthetized male
Sprague–Dawley rats (200–250 g). Briefly, the lungs were surgically removed and
bronchoalveolar lavage (BAL) was performed by repeated washing of the lungs with Ca2+
and Mg2+ free Dulbecco's PBS containing 0.5 mM disodium EDTA as described in our
previously published article [17]. The resulting BAL fluid was centrifuged to obtain pellets
of macrophages, which was then suspended in Hanks Balanced Salt Solution (HBSS). The
cells at a density of 4×105 cells/ml were then seeded onto coverslips placed in 12-well plates
and incubated in a humidified chamber at 37 °C for an h. Following incubation, an aliquot of
liposomes containing FITC-Dextran suspended in HBSS was added to the cells and
incubated again for an h at 37 °C. The cells were then fixed with acetone:methanol (1:1) at
room temperature and incubated with a blocking solution containing goat serum and Tween
20 in PBS. After this, cells were incubated with monoclonal anti-β-actin primary antibodies
(Sigma-Aldrich, St. Louis, MO) and Alexa Fluor® 594 goat anti-mouse IgG (Invitrogen,
Grand Island, NY) sequentially. Glass coverslips were placed onto glass slides and uptake of
the liposomes was observed under a fluorescence microscope (IX-81, Olympus). For uptake
of liposomes by rat pulmonary arterial smooth muscle cells (PASMCs, P-7), cells were
seeded at a density of 5×103 cells/ml and left for overnight attachment. Next day, liposomes
containing FITC-Dextran were incubated with cells for an h at 37°C in a humidified
chamber. Following incubation, cells were processed as described above and observed under
fluorescence microscope.
2.5. In-vivo drug absorption studies
The pulmonary absorption of plain fasudil and fasudil-loaded liposomes were studied in
adult male Sprague-Dawley rats (Charles River Laboratories, Charlotte, NC, USA) weighing
between 250–300 g. Four groups of rats (n = 6–8) were first anesthetized by an
intramuscular (IM) injection of ketamine and xylazine cocktail (90 mg/kg + 10 mg/kg) to
receive the following treatments: plain fasudil via (i) intravenous and (ii) intratracheal routes
at a dose of 10 mg/kg and, two liposomal formulations equivalent to 10 mg/kg fasudil, (iii)
F-3 and (iv) F-4 administered intratracheally. Intravenous administration was performed via
the penile vein and intratracheal administration was performed using a PennCentury
Microsprayer® for rats [18]. Liposomal formulations were administered as dispersions in
normal sterile saline. Following pulmonary or intravenous administration, blood samples
were collected in citrated microcentrifuge tubes at predetermined time intervals for 12 to 24
h. The plasma was separated by centrifugation at 5,000 rpm for 5 minutes and stored in
separate microcentrifuge tubes at −20°C until further analysis. The plasma levels of fasudil
were determined according to a published HPLC method [19] with little modifications using
a Varian HPLC equipped with an autosampler (Varian Prostar 320, Walnut Creek, CA). The
plasma sample was first deproteinized with perchloric acid and an aliquot of the supernatant
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(30 µl) was injected into a C18 column (Inertsil 4 µ ODS-3, 4.6 × 250 mm, GL Sciences,
Inc., CA, USA). The mobile phase was an isocratic solvent system comprised of 30%
acetonitrile and 70% phosphate buffer (0.02M, pH 7.4) and was run at a flow rate of 1 ml/
min. Fasudil eluted at 5.3 min and was detected by an UV detector at 320 nm. The drug was
quantified from a previously prepared standard curve using plain fasudil.
2.7. Safety studies
2.7.1. Cytotoxicity study—The safety of the optimized liposomal formulations (F-3 and
F-4) was evaluated using an MTT assay in two different cell lines: human airway epithelial
cells (Calu-3) and rat PASMCs [5]. Cells were seeded into 96-well plates at a density of 5 ×
104 cells per well and incubated overnight for cells to adhere to the wells. The cells were
then incubated with liposomal formulation (F-3), upon dispersion in fresh media, for 24 h
(100 µM; 100 µl per well). Saline and 0.1% SDS were used as negative and positive
controls, respectively. After the incubation, cells were washed with saline and then
incubated for an additional 4 h with 100 µl MTT (0.5 mg/ml in sterile PBS). Subsequently,
the medium was pipetted off and the formazan crystals were dissolved in 100 µl DMSO by
shaking for 1 h on a plate shaker. The absorbance was read on a SynergyMX microplate
reader (Biotek, Winnoski, VT) at 570 nm.
2.7.2. Bronchoalveolar lavage (BAL) studies—BAL studies were performed to
evaluate the safety of the optimized formulations after in vivo instillation as per our
previously published procedure [20]. Male SD rats were anesthetized with ketamine/
xylazine cocktail and divided into three groups to receive following treatments
intratracheally: (i) saline (negative control), (ii) fasudil liposomes (F-3), (iii) sodium dodecyl
sulfate (SDS, 0.1 %, positive control). Twelve h after administration of the formulations,
animals were weighed; lungs were surgically removed and weighed. The wet lung weights
were reported as g/100 g body weight. The lungs were then lavaged by instilling 5-ml of
normal saline into the trachea and collecting the fluid after 30 s. The BAL fluid was
centrifuged at 500 g for 10 min and then the supernatant was stored at −20 °C. Protein levels
in BAL fluid were assessed by Bradford assay. The enzymatic activities of lactate
dehydrogenase (LDH) and alkaline phosphatase (ALP) in BAL fluid were determined by
using commercial kits for assay of LDH and ALP (Pointe Scientific, Canton, MI).
2.8. Hemodynamic studies in monocrotaline (MCT)-induced PAH rats
The pharmacological efficacy of the formulations was studied in a rodent model of PAH.
The model was developed by a single subcutaneous injection of MCT (50 mg/kg body
weight) into adult male Sprague-Dawley rats weighing between 250 and 300 g (Charles
River Laboratories, Wilmington, MA). MCT solution was prepared by dissolving an aliquot
of MCT in 0.1 N HCl and then the pH was adjusted to 7.4 with 1 N NaOH. All animals were
housed at TTUHSC Amarillo animal facility for 28 days with free access to food and water
for developing PAH.
Four weeks later when the hypertension was established, PAH rats were anesthetized by an
intramuscular injection of a cocktail of ketamine (90 mg/kg) and xylazine (10 mg/kg) and
were divided into three groups (n=8) to receive various treatments. Before administration of
the formulations, rats were catheterized for hemodynamic measurements. For
catheterization, the ventral neck area and the dorsal area between the scapulae were shaved
and cleaned by scrubbing with Betadine® and ethyl alcohol. The internal jugular vein was
exposed by a 2–3 cm incision over the right ventral neck area and kept separated using a
suture. The right carotid artery was exposed and a PE-50 catheter (BD Intramedic™, Sparks,
MD) was inserted 3–4 cm into the artery and secured with a suture for measurement of
systemic arterial pressure. For measurement of pulmonary arterial pressure (PAP), a
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polyvinyl (PV-1, Tygon®, Lima, OH) catheter was used with the top end curved at 60–65°
angle, threaded into the pulmonary artery via the right internal jugular vein and secured with
a suture. Following catheterization, mean pulmonary arterial pressure (MPAP) and mean
systemic arterial pressure (MSAP) were measured using Memscap SP844 physiological
pressure transducers (Memscap AS, Scoppum, Norway) and bridge amplifiers connected to
PowerLab 16/30 system with LabChart Pro 7.0 software (AD Instruments, Inc., Colorado
Springs, CO). Correct positioning of the PV-1 catheter was confirmed from characteristic
shapes of the pulmonary arterial pressure tracings captured by PowerLab system as reported
previously [21]. Following measurement of hemodynamic parameters at zero time point, rats
received one of the three treatments of fasudil (3 mg/kg): (i) plain intravenous fasudil, (ii)
plain intratracheal fasudil, and (iii) liposomal formulation of fasudil (Formulation F-3)
administered intratracheally. Intravenous administration was performed via the penile vein
and intratracheal administration was performed using the PennCentury Microsprayer® as
described above. The anesthesia was maintained throughout the procedure, and blood
pressures were monitored until the pulmonary arterial pressures returned to the baseline
value observed at time zero. After completion of hemodynamic measurements, the animals
were sacrificed by exsanguination. All animal studies were performed in accordance with
NIH Guidelines for the Care and Use of Laboratory Animals under a protocol approved by
Texas Tech University Health Sciences Center (TTUHSC) Animal Care and Use Committee
(AM-10012).
2.9. Statistical Analyses
All in vitro and in vivo data are presented as mean ± SD and were analyzed by one-way
ANOVA followed by Bonferroni post-hoc analysis using Graphpad Prism 5.0 software.
Significance was defined as p value < 0.05. For pharmacokinetic analysis, standard non-
compartmental analysis (Kinetica®, Version 5.0, Innaphase Corp., Philadelphia, PA) was
performed to calculate the area of the plasma concentration-time curve from zero to 24 h.
(AUC0→24), maximum plasma concentration (Cmax), and elimination half-life (t1/2).
3. RESULTS AND DISCUSSION
3.1 Optimization and physicochemical characterization of fasudil loaded liposomes
Drug entrapment efficiency—Since fasudil is a weakly basic hydrophilic molecule
(pKa = 9.727), it exhibits very low entrapment efficiency in lipid-based formulations. For
this reason, we first optimized the entrapment efficiency of fasudil in liposomes using
passive and active loading methods and by varying drug-to-lipid ratio. Liposomes prepared
by the passive method at a drug-to-lipid molar ratio of 1.5:1 showed an entrapment
efficiency of 27.4±1.2% (Fig. 1A). To enhance the entrapment, we switched to active
loading using (NH4)2SO4 based transmembrane gradient method by varying pH of the
rehydrating medium. Using this method, we prepared four sets of formulations at different
pH values. Compared to passive loading, drug entrapment increased by 2.5 folds with
(NH4)2SO4 based transmembrane gradient method at the same drug-to-lipid molar ratio at
pH 5.4 (native) and changing the pH of the medium resulted in further increase in
entrapment efficiency. To some extent, the data suggests that the drug entrapment by active
loading method was influenced by the pH of the rehydrating medium and the highest
increase in entrapment was observed at pH 3.0 and 7.0. However, when the pH was
increased to 8.0, no further increase in entrapment was observed. We further tested the
influence of drug-to-lipid molar ratio on active loading of fasudil (Fig. 1B). The entrapment
efficiency of fasudil was 20–25% when drug-to-lipid ratios were 0.5:1 and 1:1. When the
ratio was increased to 1.5:1, a two-fold increase in loading was observed (Fig. 1B), but no
appreciable increase in entrapment efficiency was observed with the increase in molar ratio
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from 1.5:1 to 2:1. Based on these data, we considered that active loading at drug-to-lipid
ratio of 1.5:1 was optimum with substantial drug entrapment.
These data agree with previous studies wherein (NH4)2SO4 based remote loading was used
to increase entrapment efficiency of hydrophilic drugs. In fact, low encapsulation of
hydrophilic drugs has been a limitation when small unilamellar vesicles (SUV) are to be
used as drug delivery carriers [22]. Similar to fasudil, weak bases including doxorubicin and
hydromorphone have been successfully encapsulated in preformed liposomes utilizing
transmembrane gradient [23–26]. For example, Caelyx®, a PEGylated liposomal
formulation of doxorubicin, was prepared using ammonium sulfate gradient for generating
indirect pH-gradient. In this method, the presence of ammonium sulfate in the core of
liposomes produces an excess availability of protons inside the vesicle because of removal
of ammonium sulfate from the extraliposomal compartment resulting in a proton gradient
across the liposomal membrane [27]. Unprotonated weak bases outside the vesicles can
easily permeate through liposomal membranes. Once inside the vesicles, they are protonated
in H+ rich environment and thereby trapped in the aqueous core of the vesicles [27].
Enhanced entrapment may also result from incubation of the drug with preformed liposomes
at 65°C, which is consistent with previous assumption that unprotonated amphipathic bases
are trapped within the liposomes when incubated at temperatures higher than phase
transition temperatures of lipids for 30 minutes [28]. In fact, a 30-minute incubation time is
reported to be optimal for maximal drug entrapment. Incubation beyond 30 minutes
apparently reduces entrapment efficiency because of formation of neutral complexes
between protonated fasudil and sulfate (SO4−2) ions, which tend to effuse though liposomal
membrane [19]. No additional entrapment was observed with the increase in pH from 3.0 to
7.0 or 8.0 perhaps because of reduction of proton gradient that may result from reduced
protonation of (NH4)2SO4 at pH as high as 7.0 or 8.0. The entrapment efficiency data
suggest that ammonium sulfate based active loading is one of the most efficient methods of
encapsulation of fasudil in liposomes.
However, this data raise questions regarding the influence of pH gradient on the entrapment
efficiency. In fact, similar anomaly in entrapment efficiency was observed when Ishida et al.
[19] varied pH and concentration of ammonium sulfate to study the influence of proton and
ammonium sulfate gradient on the entrapment of fasudil into liposomes. Similar to the data
presented in this manuscript, no appreciable increase in drug entrapment was observed when
pH was varied. But the entrapment efficiency was increased when concentration of
ammonium sulfate was increased. The authors theorized that pH gradient has perhaps a
limited role in controlling entrapment of fasudil, a weakly basic drug (pKa of 9.727) [19].
Based on this published study and our data, we assume that ammonium sulfate gradient is
perhaps the major player in enhancing drug loading.
Particle size and morphology—Upon efficient encapsulation of liposomes, particle
size, polydispersity index, and morphology of various liposomal preparations were
evaluated. The gradient produced by the presence of (NH4)2SO4 in the vesicle core
significantly influenced the size of liposomes. Compared to liposomes prepared without pH
gradient, an overall reduction was observed in the size of liposomes prepared with
(NH4)2SO4 in combination with pH gradient (Fig. 1C). In the absence of transmembrane
gradient, the size of liposomes was 288.7±9.9 nm, which was decreased to 140.6±0.7 nm for
the formulation with active loading at the pH of 5.4 (Fig. 1C). Such reduction in particle size
can be explained by the changes in pH around the lipids during liposome preparation as
observed by others [29, 30]. It has also been suggested that reduction in particle size results
from an effect of osmotic stress produced by concentration and pH gradients. However, the
size of liposomes prepared by (NH4)2SO4 gradient was in the range of 100 and 250 nm,
which puts them under the category of SUVs as reported by others [31]. The SUV like size
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distribution of the liposomes suggest that hydration followed by sonication can be used for
preparation of SUVs. Due to their small size, these liposomal formulations are expected to
be optimal for in-vivo efficacy and avoid clearance by alveolar macrophages. Further, all
liposomal formulations prepared by (NH4)2SO4 and pH gradient method had a
polydispersity index (PDI) in the range of 0.15 and 0.2 (Table 1), suggesting that the
formulations had a homogenous size distribution. Transmission electron microscopic (TEM)
image presented in Fig. 1D exhibit round or oval liposomes with a smooth surface. The
formulations showed little or no aggregations indicating that the vesicles were uniformly
dispersed in extraliposomal fluid. TEM has previously been used for examining the lamellar
morphology, bilayer organization, and identification of possible flaws in bilayers [32].
However, the TEM photographs showed no morphological or structural changes due to
incorporation of ammonium sulfate in the liposome core. Rather, we observed a uniform bed
of discrete spherical vesicles that agree with vesicle size data obtained by the dynamic light
scattering technique.
3.2 In-vitro Drug Release
The in-vitro drug release studies were performed to test the hypothesis that encapsulation of
fasudil in lipidic SUVs produce sustained drug release in physiological fluid. The in-vitro
release profile of the liposomal formulations obtained in PBS buffer at 37°C showed a
continuous release of the drug for about 40 h (Fig. 2A). But 100% of plain fasudil was
released in the media (data not shown) suggesting that dialysis cassettes were not the rate
controlling membrane for drug release. The time required to release 50% of the drug was in
the range of 8 to 12 h for F-1, F-2, and F-5 formulations and that for F-3, and F-4 was ~24 h.
During the first 24 h, F-3 and F-4 produced 51.2±0.5% and 46.2±0.7% drug release,
respectively (Fig. 2A). Since the amount of drug release was relatively small, one may
question about the stability of the drug in release media. In fact, a published report suggests
that fasudil is stable over an extended period of time (~24 weeks) at various storage
conditions [19]. Further, we have used an HPLC method to quantitate fasudil in vivo which
is sensitive to only intact fasudil rather than degradation products of fasudil. Thus it is
unlikely that drug underwent degradation during the study period. Further, F-5 exhibited no
burst release as evidenced from the negligible amount of drug released during first 30
minutes, but F-3 and F-4 formulations showed 9.1±1.4% and 11.8±2.7% drug release during
the burst release phase (Fig. 2B). A slower and consistent release of fasudil from liposomal
formulations suggests that drug release was due to diffusion of the drug though lipid
membranes rather than disruption of the SUVs. These data agree with previous studies with
liposomal fasudil [19], where carboxyfluorescien, an aqueous phase marker, was
encapsulated in liposomes, and only 15% of the dye was released during a 14-day
experiment [19]. In fact, the similarity among release profiles from various formulations
stem from the fact that there were no differences in the type and amount of lipid used to
prepare the formulations. The diffusion of the drug from the vesicles can be explained by
interaction of protonated fasudil molecule with the sulfate ions in vesicle core. As discussed
above, upon entering the hydrophilic core, unprotonated fasudil becomes protonated in H+
rich environment in the core and forms electrochemically neutral complexes with anionic
sulfates (SO4−−) [33]. The resulting uncharged complex then diffuses out from the core via
the lipid bilayer. Further, as the phase transition temperature for DPPC is 41°C, which is
close to the physiological temperature, 37°C, it is reasonable to assume that the principal
mechanism for drug release from liposomal formulations is diffusion of the
electrochemically neutral fasudil complex through liquefied lipid membranes. This
assumption is consistent with a previous study that evaluated temperature dependent phase
transition of DPPC liposomal systems and showed that DPPC vesicles of >100 nm undergo
phase transition at around 37–39°C [34]. Further, encapsulation of small molecules such as
fasudil is unlikely to alter phase transition properties of lipid vesicles at high drug to lipid
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ratios. Overall, the in-vitro release data suggest that F-3 and F-4 formulations would be
efficacious in delivering fasudil in the distal pulmonary arterioles for a prolonged period of
time and would likely provide sustained vasodilation.
3.4. In-vitro Stability Studies
Reduction in drug entrapment due to drug leakage and aggregation of vesicles are major
concerns with the stability of liposomal formulations. To examine the stability of liposomal
formulations, we assessed the changes in particle size and drug entrapment of F-3 and F-4
formulations which showed maximal loading. The formulations were stored at 4°C and
25°C, and the particle size and drug entrapments were monitored for 4 weeks. No changes in
vesicle size was observed in formulations stored at 4°C and 25°C, suggesting that the
vesicles remained well separated from each other and formed no aggregates during the
storage period (Fig. 3A). Therefore, no change in particle size can be attributed to the
stability provided by the optimum zeta potential which prevents the particles from
coalescing and aggregating. When stored at 4°C, no change in drug entrapment was
observed for 21 days, but a 10–15% reduction in drug entrapment was observed upon
storage for 28 days (Fig. 3B). However, storage at room temperature (25°C) resulted in
about 30–35% drug loss over 28 days, which is 2–3 times higher than drug loss that
occurred upon storage at 4°C. Moreover the lipids, cholesterol and phospholipid, used to
prepare liposomes are unlikely to undergo degradation during storage at 4°C [27] and it has
also been shown that liposomal formulations can release drugs from 2 weeks to as long as
several months [35], indicating that the integrity of liposomes is unlikely to be adversely
affected in the physiological fluid.
In addition to studying the stability at various storage temperatures, we also studied stability
upon aerosolization. In fact, aerosolization breaks larger droplets into smaller ones and
delivers the formulations in the form of fine mists. But the force applied for nebulization
may rupture the liposomes and release the drug prematurely. This may also result in leakage
of drugs from some liposomes. To test this, we nebulized the formulation 5 times to mimic
intratracheal administration into rats and evaluated various physicochemical properties of
liposomes. The data presented in Table 2 show that there were no significant differences in
vesicle size, polydispersity index and entrapment efficiency before and after nebulization of
the liposomes, suggesting that liposomal integrity was not affected due to the force applied
to administer the formulations using PennCentury Microsprayers®.
3.5. Uptake of liposomes by rat alveolar macrophages and PASMCs
Alveolar macrophages, present on lung epithelial surfaces and responsible for engulfing and
clearing of inhaled particles, may influence the clearance of liposomal formulations. Further,
previously published reports suggest that particles less than 250 nm can escape clearance by
macrophages [36]. Microscopic images suggest little or no uptake of liposomes by
macrophages (Fig. 4A), indicating that liposomes were not cleared via macrophageal uptake
mechanism. Particles are intended to produce their therapeutic response in smooth muscle
cells by inhibiting Rho-kinase and hence reduce mean pulmonary arterial pressure. To
demonstrate this, we performed another set of experiment using rat PASMCs and observed
that there was significant uptake of liposomes by these cells (Fig. 4B). Superimposed images
of FITC (green) and TRITC (red) channels show the localization, as visualized by yellow
fluorescence, indicating that liposomal formulations can act on vascular smooth muscles and
produce therapeutic effect of the drug. Further transport studies using cells of airway
epithelium are required to track the movement of fasudil or liposomes across the pulmonary
vasculature.
Gupta et al. Page 9
J Control Release. Author manuscript; available in PMC 2014 April 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
3.6 In-vivo Absorption Studies
In pulmonary absorption studies, the pharmacokinetics of two formulations with maximal
drug loading (F-3 and F-4) were compared with that of plain fasudil administered via
intravenous or pulmonary routes (Fig. 5). Intravenous administration of fasudil resulted in a
quick rise in drug plasma concentrations with a Cmax of 298±10 ng/ml followed by a rapid
decline (Fig. 5A), whereas pulmonary administration of plain fasudil resulted in an
appreciable increase in plasma concentrations (Cmax = 66.2±13.6 ng/ml, Fig. 5A). Unlike
intravenous route, the elimination of fasudil administered by pulmonary route was slow
(Fig. 5A and Table 3), which is evident from the differences in elimination half-lives of
fasudil administered by the two routes. The elimination half-life (t1/2) of fasudil
administered by pulmonary route (1.17±0.21 h.) was significantly higher than that of fasudil
given intravenously (t1/2 = 0.39±0.12 h.) (p<0.05) (Fig. 5A, Table 3). The relative
bioavailability of fasudil after pulmonary administration was ≈40% (Table 3). However, the
pharmacokinetic profiles observed after intratracheal administration of two liposomal
formulations (F-3 and F-4) were completely different from those observed with plain
intratracheal and intravenous fasudil (Fig. 5B). F-3 formulation showed a Cmax of 89.4±29.7
ng/ml at 8 h. followed by a sharp decline in plasma fasudil levels with no detectable
concentrations at 18 h. Similarly, F-4 formulation produced a Cmax of 86.9±11.9 ng/ml at 2
h. Pharmacokinetic analysis of the in-vivo data revealed that fasudil liposomes resulted in a
remarkable extension of elimination t1/2 (4.71±0.72 h. for F-3 and 3.44±0.49 h. for F-4). In
fact, t1/2 of both formulations was ~3–4 and 10 times, respectively longer than plain fasudil
after pulmonary and intravenous administration. The IC50 of fasudil against Rho-kinase is
reported to be between 1.9–3.7 µM [37, 38]. Based on the published data we assume that the
plasma concentrations of fasudil were above therapeutic levels for at least 15 h with
liposomal formulations, which can be translated into a once-a-day or twice-a-day dosing
regimen. Similar to in vitro data, in-vivo absorption profiles also show a trend of extended
release although the two profiles were not similar. Differences between in vitro release and
in vivo absorption profiles can be attributed to a number of factors including mechanisms of
absorption, distribution and elimination of liposomes administered via the pulmonary,
physicochemical characteristics of the aerosolized liposomes, macrophage dependent
clearance, lipid degrading enzymes, and transport of intact liposomes from lungs to the
systemic circulation, metabolic degradation and protein binding. Further, sustained release
behavior of liposomes may also result from multiple factors. First, upon inhalation,
liposomes may act as reservoirs that remain submerged in the respiratory fluid and release
the drug continuously. In fact, particulate carriers with particle size below 1 µm can avoid
phagocytosis by alveolar macrophages [39, 40] and thereby perhaps form aggregates in the
respiratory mucosa and act like reservoirs or depot. Based on this assumption, the drug is
expected to be released from the liposomes by diffusion though lipid bilayer. Release of the
drug due to rupture of liposomal bilayer is unlikely since lipids used are resistant to
degradation by enzymes present in respiratory mucosa [41, 42]. However, dissolution of
liposomes in the surfactant rich respiratory fluid cannot be ruled out. A fraction of the drug
is likely to be released due to dissolution of liposomes in the respiratory mucosa. In either
case, drug released from liposomes will traverse the blood airway barrier and enter arterioles
via the adventitial side to produce its vasodilatory effects. A second mechanism for
sustained release of the drug may involve transport of intact liposomes or released drug to
the systemic circulation via the air-blood barrier. Upon entering the systemic circulation
fasudil may diffuse out of the liposomes to the systemic circulation. Fasudil in the
circulating blood enters the smooth muscles of the pulmonary arterioles from the endothelial
side to produce its therapeutic effect. Further studies using ex-vivo models such as isolated
perfused lungs are required to assess the relative contribution of above described absorptive
mechanisms upon intratracheal administration of liposomes. However, one of the important
limitations of this in vivo study is that it was performed in healthy animals. Since PAH
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animals undergo several pathological changes, pharmacokinetics of the drug in PAH rats
could be slightly different from those observed in healthy animals. Future studies should
delineate the differences between the pharmacokinetics of the drug in healthy and diseased
animals.
Safety Studies—In-vitro cytotoxicity studies were performed to determine the effects of
liposomal formulations on two different cell lines: Calu-3 and rat PASMCs. Cells were
treated with saline (negative control) and 0.1% w/v sodium dodecyl sulfate (SDS) (positive
control) showed cell viability of 99% and 15%, respectively (Fig. 6A). When Calu-3 cells
were treated with 100 µM F-3 formulations for 24 h, the cell viability was 86.19±13.66%
(Fig. 6A). One primary cell line (rat PASMCs) treated with 100 µM of liposomes for 24 h
showed similar cell viability. In none of the cases was cell viability below 70%, suggesting
that formulations were toxic neither to immortalized Calu-3 cells nor to primary PASMCs.
These observations were expected since lipids used to prepare liposomes have long been
known to produce little or no cytotoxicity.
To further evaluate the safety, BAL was performed after taking weights of wet lungs as
discussed above in the method section. The weight of wet lungs, expressed in lung weight
per 100 g of body weight (L/B), of saline treated animals was 0.397±0.0047 and that for
SDS treated animals was 0.614±0.0368 (Fig. 6B), suggesting formation of edema due to
accumulation of extracellular fluid into the epithelial cells of the respiratory wall in SDS
treated lungs. For liposomal formulation containing fasudil (F-3), L/B ratio was
0.42±0.0116, indicating no substantial lung injury or edema formation. The levels of two
injury markers, LDH and ALP, as well as total protein concentration in the BAL collected
from animals treated with formulation F-3 were not significantly different from that
observed in the lungs of animals that received saline (Fig. 6C and 6D) which were
significantly higher in SDS treated animals. Overall, data presented in Fig. 6 establish the
safety profile of liposome based formulations after single administration, but long-term
safety profiles of fasudil formulations after multiple administrations should be evaluated.
3.7 Efficacy of Liposomal Fasudil in PAH Rats
The pharmacological efficacy of the formulations in reducing mean pulmonary arterial
pressure (MPAP) was studied in an MCT induced rat model of PAH. The signs induced by a
single subcutaneous injection of MCT (50–60 mg/kg) resemble those of clinical PAH that
include increased MPAP, right ventricular hypertrophy, pulmonary vascular remodeling,
and reduced luminal diameter of small pulmonary arterioles [43, 44]. In this study, the
average MPAP was 38.0±9.4 mm Hg 4 weeks after MCT injection as compared to 15.6±4.4
mm Hg in sham animals. In agreement with earlier reports [14, 45, 46], intravenous
administration of plain fasudil (3 mg/kg) produced a 45.6±17.0% decrease in MPAP, but its
vasodilatory effect quickly subsided within 60 to 80 minutes (Fig. 7A). Intratracheal
administration of plain fasudil also caused a 38.3±7.3% decrease in MPAP, although the
duration of the vasodilatory effect was slightly longer than that produced by intravenous
fasudil (Fig. 7A and 7C). However, when liposomal fasudil (Formulation F-3) was
administered via the pulmonary route, the duration of vasodilatory effect was extended up to
200 minutes (Fig. 7A). The maximal reduction in MPAP produced by liposomal fasudil was
37.6±5.7% which was similar to that produced by plain fasudil administered via either route.
However, unlike plain fasudil administered intravenously or intratracheally, liposomal
fasudil continued to produce pulmonary vasodilation even 3.5 h post instillation, i.e., a
20.0±8.7% reduction in MPAP at 200 minutes (Fig. 7A). The data concerning the
pharmacological efficacy presented in Fig. 7 reflects the absorption profile of the
formulation presented in Fig. 5, wherein the t1/2 of liposomal fasudil was significantly
longer than that of plain fasudil. To calculate the duration of pulmonary vasodilatory effects,
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we used 15% reduction in MPAP as baseline and plotted the values to compare the duration
of three treatments. This baseline was chosen based on previous studies that show a 15 to
20% reduction in MPAP is therapeutically relevant and significant [47]. The liposomal
fasudil maintained pulmonary vasodilatory effects for 3 h. (172±17 minutes) while
intravenous and pulmonary plain fasudil caused vasodilation for 50.0±10.4 and 60.0±15.3
minutes, respectively (Fig. 7C). These data further confirm that liposomal fasudil produced a
prolonged vasodilation that would offer therapeutic advantages over the plain drug.
However, concerns may be raised regarding the candidacy of fasudil as a drug for
development into controlled formulations. Since the effective dose in animal was 3 mg/kg,
one might argue that a much larger dose (200–300 mg) would be required in humans and
thus the proposed formulation would be not be viable for use in human patients. But
calculation of human dose based on the allometric [48] and body surface area principles [49]
suggest that 3 mg/kg dose in rats is equivalent to ~35–40 mg in 70-kg human subjects. In
fact, fasudil used at a dose of 30 or 40 mg was found to effective in reducing MPAP in PAH
patients [45, 50]. Thus this study provides convincing data in support of an inhaled
controlled release formulation of fasudil for the treatment of PAH.
To evaluate the pulmonary selectivity of the formulation, we also measured the mean
systemic arterial pressure (MSAP) and calculated the reduction in MSAP produced by the
formulations (Fig. 7B). Intravenous and intratracheal fasudil produced a 45.6±8.4% and
38.1±10.8% reduction in MSAP, respectively (Fig. 7B). The extent of reduction of MSAP
produced by plain fasudil was close to that observed in MPAP (Fig. 7A), suggesting that
fasudil when given intravenously does not exhibit much selectivity toward the pulmonary
circulation and thus produces peripheral vasodilation. However, intratracheal liposomal
fasudil produced a 26.4±7.4% reduction in MSAP, which was significantly less (p<0.05)
than that produced by intravenous and intratracheal plain fasudil. A point-by-point
comparison of hemodynamic data presented in Fig. 7B also suggests that the reduction in
systemic arterial pressure produced by aerosolized liposomal fasudil was consistently lower
than that produced by plain fasudil administered either by intravenous or pulmonary route.
In addition to pulmonary selectivity, fasudil encapsulated in liposomes is likely to reduce the
dosing frequency and minimize the fluctuations in MSAP due to multiple injections or
continuous infusion that leads to serious side effects including syncope and cardiovascular
collapse [51]. Overall, the hemodynamic study suggests that intratracheal instillation of
fasudil encapsulated in liposomes was therapeutically active and the drug was released from
liposomes over time. There was a continuous influx of fasudil into the pulmonary arteries
that provided sustained vasodilation with reduced effect on systemic arterial pressure than
that of plain fasudil. These data are in agreement with in-vivo absorption profile wherein a
continuous absorption of fasudil was observed. However, the in vivo efficacy study was
limited to evaluation of only one of the pharmacological parameters, mean pulmonary
arterial pressures. Evaluation of other parameters such as influence of the formulations in
reducing vascular resistance and ameliorating other pathological changes in PAH would
have provided more useful information regarding the therapeutic benefit of liposomal
fasudil. Future studies will be directed toward assessing various cellular and vascular
markers upon administration of the formulations.
4. CONCLUSIONS
In summary, this is the first study to investigate the feasibility of an aerosolized controlled
release formulation of fasudil that produces a sustained pulmonary preferential vasodilation
and ameliorates the severity of MCT-induced PAH. Liposomal formulations can be used as
vehicles for pulmonary delivery of fasudil as demonstrated by favorable physicochemical
properties. The drug exhibited an extended t1/2 following in-vivo administration in rats.
Compared to intravenous fasudil, a single dose of the optimized liposomal formulations
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produced sustained pulmonary vasodilation for ~3 h and produced minimal impact on
MSAP. Nanosized liposomes were safe after intratracheal delivery, escaped clearance by
alveolar macrophages and were internalized by PASMCs. Thus, the data presented suggest
that aerosolized liposomes of fasudil can be used for sustained and pulmonary preferential
vasodilation at a reduced dosing frequency and can potentially be used as a viable anti-PAH
therapy. However, further studies are required to establish the long-term efficacy of fasudil
liposomes in providing protection against PAH related lesions.
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Figure 1.
(A) % Drug entrapment upon passive and active loading at a drug-to-lipid molar ratio of
1.5:1, (B) Influence of drug-to-lipid molar ratio on entrapment efficiency upon active
loading, (C) vesicle size of liposomes, and (D) respresentative transmission electron
microscopic image of fasudil loaded liposomes. Data represent mean ± standard deviation (n
= 3). *Results are significantly different (p < 0.05), (A) F-3 and F-4 compared with F-1 and
(B) molar ratio 1.5 compared with 0.5.
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Figure 2.
In-vitro release profiles of fasudil-loaded liposomal formulations in PBS (pH 7.4) at 37°C:
(A) Release profiles of liposomes F-1 through F-5, and (B) Release kinetics showing burst
release (release in first 30 minutes) and % release rate/hr. Data represent mean ± standard
deviation (n = 3).
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Figure 3.
Influence of storage temperature and length of storage on (A) particle size and (B) drug
entrapment efficiency Formulations were stored at 4°C and 25°C over a period of 4 weeks.
Data represent mean ± standard deviation (n = 3).
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Figure 4.
Intracellular uptake of liposomes containing fasudil by (A) rat alveolar macrophages, and
(B) rat pulmonary arterial smooth muscle cells. (i) overlay; (ii) TRITC channel; and (iii)
FITC channel.
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Figure 5.
In-vivo absorption profiles: (A) Plain fasudil administered via intravenous and intratracheal
routes at a dose of 10 mg/kg, and (B) Liposomal fasudil formulations administered
intratracheally at a dose of 10 mg/kg. Data represent mean ± standard deviation (n = 6–8).
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Figure 6.
Safety studies (A) cytotoxicity studies of fasudil liposomes (100 µM) in human bronchial
epithelial (Calu-3) and rat pulmonary arterial smooth muscle (PASM) cells for 24 hrs (n =
8). Effect of the formulation on the (B) wet lung weight, (C) total protein content, and (D)
levels of injury markers in bronchioalveolar lavage (BAL) fluid. Data represent mean ⊠ s.d.
(n=4), *means are significantly different (p<0.05), 0.1% SDS treatment is compared with
fasudil liposomes.
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Figure 7.
Hemodynamic efficacy of the formulations in MCT induced PAH rats in reducing (A) mean
pulmonary arterial pressure (MPAP) [horizontal dashed line (----) represents 15% reduction
in MPAP] and (B) mean systemic arterial pressure upon administration of plain and
liposomal fasudil at a single dose of 3 mg/kg. (C) Duration of pulmonary vasodilatory
effects calculated using 15% reduction in MPAP as the baseline at the start and end points of
MPAP recording. Data represent mean ± standard deviation (n = 4–6). *Means are
significantly different from each other (p < 0.05).
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Table 2
Physicochemical characterization of fasudil loaded liposomes before and after nebulization with the
microsprayer:
Nebulization Size (nm) PDI Zeta
Potential
(mV)
Entrapment
Efficiency
(%)
No 180.067±5.464 0.92±0.004 −17.3±0.476 63.69±1.748
Yes 180.567±1.95 0.85±0.012 −16.9±0.929 63.18±0.891
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